Biosenta Inc (TSE:ZRO)
:ZRO
Want to see TSE:ZRO full AI Analyst Report?
ZRO Stock Chart & Stats
C$0.08
-C$0.03(-11.36%)
At close: 4:00 PM EST
C$0.08
-C$0.03(-11.36%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.17
Previous CloseN/A
Volume1.00K
Average Volume (3M)2.93K
Market Cap
C$1.74M
Enterprise ValueC$2.60M
Total Cash (Recent Filing)C$7.81K
Total Debt (Recent Filing)C$865.55K
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,768,887
10 Day Avg. Volume5,790
30 Day Avg. Volume2,930
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-0.40
Price to Sales (P/S)3296.23
P/FCF Ratio-8.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Free Cash Flow BurnFree cash flow burn improved versus 2024 annual levels, reducing near-term financing pressure. If sustained, this extends operational runway and lowers dilution risk, providing management more time to stabilize operations or execute restructuring over the next several months.
Cash Flow Quality Aligns With EarningsFree cash flow roughly equals net income (near 1x), indicating losses reflect real cash outflows rather than large non-cash accounting items. This alignment improves predictability of cash needs and planning, making financing and turnaround modelling more reliable.
Debt Below Prior PeakTotal debt (~866K TTM) is stated below 2024’s peak, suggesting some deleveraging versus prior highs. Reduced peak leverage, if persistent, eases solvency pressure and modestly improves flexibility for refinancing or securing incremental capital.
Bears Say
Deeply Negative Shareholders' EquityDeeply negative equity (~-10.6M) against a tiny asset base (~92K) indicates accumulated deficits dominate capital structure. This structural insolvency constrains access to capital, limits strategic options, and creates a high risk of dilution or recapitalization needs absent material improvement.
Tiny, Shrinking Revenue And Negative Gross ProfitVery small, declining revenue (TTM ~940, -22% YoY) combined with negative gross profit shows the business lacks scale and margin viability. Without structural revenue recovery or cost reengineering, profitability remains unlikely and long-term sustainability is impaired.
Persistent Operating Cash BurnOngoing negative operating and free cash flow (~-447K to -449K TTM) signals persistent cash burn requiring external funding or asset actions. Continued outflows threaten continuity and force tough tradeoffs between growth, cost cuts, or dilutive financing absent revenue turnaround.
Biosenta Inc News
ZRO FAQ
What was Biosenta Inc’s price range in the past 12 months?
Biosenta Inc lowest stock price was C$0.05 and its highest was C$0.17 in the past 12 months.
What is Biosenta Inc’s market cap?
Biosenta Inc’s market cap is C$1.74M.
When is Biosenta Inc’s upcoming earnings report date?
Biosenta Inc’s upcoming earnings report date is Jun 03, 2026 which is in 32 days.
How were Biosenta Inc’s earnings last quarter?
Currently, no data Available
Is Biosenta Inc overvalued?
According to Wall Street analysts Biosenta Inc’s price is currently Overvalued.
Does Biosenta Inc pay dividends?
Biosenta Inc does not currently pay dividends.
What is Biosenta Inc’s EPS estimate?
Biosenta Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosenta Inc have?
Biosenta Inc has 34,768,887 shares outstanding.
What happened to Biosenta Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biosenta Inc?
Currently, no hedge funds are holding shares in TSE:ZRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biosenta Inc
Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada. It is involved in developing true, an anti-microbial, dual-action disinfectant that kills viruses, bacteria, mold, and germs on contact. The company also intends to manufacture and distribute Tri-Filler, an anti-microbial filler to perform filling and bulking functions. Biosenta Inc. was founded in 1986 and is based in Toronto, Canada.
Technical Analysis
BioNeutra Global
―
Lifeist Wellness
―
Psyched Wellness
―
Happy Supplements Inc.
―
Pure to Pure Beauty Inc.
―